Quantrx Biomedical
QuantRx Biomedical Corporation engages in the development and commercialization of patented miniform pads (PADs) and PAD based over-the-counter products in the United States. It is also developing genomic diagnostics for the laboratory market based on its lateral flow patents, including RapidSense technology, a one-step lateral flow test. The company's PAD products are used for the treatment of h… Read more
Quantrx Biomedical (QTXB) - Net Assets
Latest net assets as of September 2022: $-2.84 Million USD
Based on the latest financial reports, Quantrx Biomedical (QTXB) has net assets worth $-2.84 Million USD as of September 2022.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.38K) and total liabilities ($2.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-2.84 Million |
| % of Total Assets | -52769.18% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 153.2 |
Quantrx Biomedical - Net Assets Trend (1994–2021)
This chart illustrates how Quantrx Biomedical's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Quantrx Biomedical (1994–2021)
The table below shows the annual net assets of Quantrx Biomedical from 1994 to 2021.
| Year | Net Assets | Change |
|---|---|---|
| 2021-12-31 | $-2.64 Million | -10.92% |
| 2020-12-31 | $-2.38 Million | -11.87% |
| 2019-12-31 | $-2.13 Million | -41.29% |
| 2018-12-31 | $-1.51 Million | -100.97% |
| 2017-12-31 | $-749.55K | +55.34% |
| 2016-12-31 | $-1.68 Million | -17.20% |
| 2015-12-31 | $-1.43 Million | -17.88% |
| 2014-12-31 | $-1.21 Million | -76.11% |
| 2013-12-31 | $-689.87K | -81.77% |
| 2012-12-31 | $-379.54K | -380.96% |
| 2011-12-31 | $135.09K | -70.39% |
| 2010-12-31 | $456.25K | +2184.86% |
| 2009-12-31 | $-21.88K | +99.30% |
| 2008-12-31 | $-3.13 Million | -270.30% |
| 2007-12-31 | $1.84 Million | -48.44% |
| 2006-12-31 | $3.57 Million | +238.13% |
| 2005-12-31 | $1.05 Million | +297.41% |
| 2004-12-31 | $-534.27K | +48.11% |
| 2003-12-31 | $-1.03 Million | -4.72% |
| 2002-12-31 | $-983.14K | -11.72% |
| 2001-12-31 | $-880.00K | -363.16% |
| 2000-12-31 | $-190.00K | -129.69% |
| 1999-12-31 | $640.00K | -13.51% |
| 1998-12-31 | $740.00K | +1.37% |
| 1997-12-31 | $730.00K | -5.19% |
| 1996-12-31 | $770.00K | -75.86% |
| 1995-12-31 | $3.19 Million | +30.20% |
| 1994-12-31 | $2.45 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Quantrx Biomedical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5116502800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2021)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $786.96K | % |
| Other Comprehensive Income | $8.60K | % |
| Other Components | $48.94 Million | % |
| Total Equity | $-2.64 Million | 100.00% |
Quantrx Biomedical Competitors by Market Cap
The table below lists competitors of Quantrx Biomedical ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
VALUE-HLDG INT
BE:NW4
|
$31.99K |
|
IBKS No. 22 Special Purpose Acquisition co.
KO:448760
|
$31.99K |
|
PRNR3F
SA:PRNR3F
|
$32.02K |
|
Secure Trust Bank PLC
LSE:STB
|
$32.03K |
|
LINGBAO GOLD -H- (LI9.SG)
STU:LI9
|
$31.94K |
|
CRPG3F
SA:CRPG3F
|
$31.94K |
|
Aquila SA
PA:ALAQU
|
$31.93K |
|
BMIN3F
SA:BMIN3F
|
$31.93K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Quantrx Biomedical's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2020 to 2021, total equity changed from -2,381,055 to -2,641,097, a change of -260,042.
- Net loss of 476,701 reduced equity.
- Other factors increased equity by 216,659.
Equity Change Factors (2020 to 2021)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-476.70K | -18.05% |
| Other Changes | $216.66K | +8.2% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Quantrx Biomedical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1994-12-31 | $0.49 | $0.00 | x |
| 1995-12-31 | $0.40 | $0.00 | x |
| 1996-12-31 | $0.08 | $0.00 | x |
| 1997-12-31 | $0.06 | $0.00 | x |
| 1998-12-31 | $0.06 | $0.00 | x |
| 1999-12-31 | $0.07 | $0.00 | x |
| 2000-12-31 | $-0.02 | $0.00 | x |
| 2001-12-31 | $-0.09 | $0.00 | x |
| 2002-12-31 | $-0.10 | $0.00 | x |
| 2003-12-31 | $-0.10 | $0.00 | x |
| 2004-12-31 | $-0.04 | $0.00 | x |
| 2005-12-31 | $0.07 | $0.00 | x |
| 2006-12-31 | $0.12 | $0.00 | x |
| 2007-12-31 | $0.05 | $0.00 | x |
| 2008-12-31 | $-0.07 | $0.00 | x |
| 2009-12-31 | $0.00 | $0.00 | x |
| 2010-12-31 | $0.01 | $0.00 | x |
| 2011-12-31 | $0.00 | $0.00 | x |
| 2012-12-31 | $-0.01 | $0.00 | x |
| 2013-12-31 | $-0.01 | $0.00 | x |
| 2014-12-31 | $-0.02 | $0.00 | x |
| 2015-12-31 | $-0.02 | $0.00 | x |
| 2016-12-31 | $-0.02 | $0.00 | x |
| 2017-12-31 | $-0.01 | $0.00 | x |
| 2018-12-31 | $-0.02 | $0.00 | x |
| 2019-12-31 | $-0.03 | $0.00 | x |
| 2020-12-31 | $-0.03 | $0.00 | x |
| 2021-12-31 | $-0.03 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Quantrx Biomedical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-109.65%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1994 | -42.86% | 0.00% | 0.00x | 1.91x | $-1.29 Million |
| 1995 | -131.66% | -8400.00% | 0.01x | 1.09x | $-4.52 Million |
| 1996 | -562.34% | -2278.95% | 0.10x | 2.57x | $-4.41 Million |
| 1997 | -272.60% | -2211.11% | 0.05x | 2.70x | $-2.06 Million |
| 1998 | -625.68% | -1102.38% | 0.22x | 2.55x | $-4.70 Million |
| 1999 | -389.06% | -3557.14% | 0.05x | 2.13x | $-2.55 Million |
| 2000 | 0.00% | -6066.67% | 0.05x | 0.00x | $-1.80 Million |
| 2001 | 0.00% | -8700.00% | 0.03x | 0.00x | $-781.00K |
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $-25.72K |
| 2003 | 0.00% | -104.45% | 0.48x | 0.00x | $56.55K |
| 2004 | 0.00% | -29.90% | 0.35x | 0.00x | $33.58K |
| 2005 | -103.59% | -1963.44% | 0.04x | 1.25x | $-1.20 Million |
| 2006 | -215.70% | -8410.52% | 0.02x | 1.21x | $-8.05 Million |
| 2007 | -328.70% | -809.02% | 0.20x | 1.99x | $-6.23 Million |
| 2008 | 0.00% | -1236.42% | 0.18x | 0.00x | $-7.41 Million |
| 2009 | 0.00% | -123.60% | 1.90x | 0.00x | $-3.15 Million |
| 2010 | 182.18% | 55.65% | 1.15x | 2.85x | $785.56K |
| 2011 | -580.08% | -4105.93% | 0.03x | 4.34x | $-797.12K |
| 2012 | 0.00% | -4712.31% | 0.03x | 0.00x | $-680.01K |
| 2013 | 0.00% | -5861.79% | 0.02x | 0.00x | $-289.34K |
| 2014 | 0.00% | -34032.30% | 0.00x | 0.00x | $-705.49K |
| 2015 | 0.00% | -299858.97% | 0.00x | 0.00x | $-324.56K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-230.14K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $944.09K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-586.21K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-607.27K |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-231.35K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-212.59K |
Industry Comparison
This section compares Quantrx Biomedical's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,683,526,542
- Average return on equity (ROE) among peers: -32.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Quantrx Biomedical (QTXB) | $-2.84 Million | -42.86% | N/A | $31.97K |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $480.24 Million | 2.52% | 0.41x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $19.68 Billion | 1.70% | 0.48x | $37.82 Billion |
| Align Technology Inc (ALGN) | $3.85 Billion | 10.94% | 0.61x | $11.75 Billion |
| AngioDynamics Inc (ANGO) | $355.71 Million | 3.06% | 0.15x | $354.40 Million |
| Ansell Limited (ANSLF) | $386.33 Million | -0.45% | 0.87x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $8.27 Billion |
| AtriCure Inc (ATRC) | $72.60 Million | -15.79% | 0.54x | $1.42 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $9.03 Million | -338.35% | 0.77x | $156.14 Million |